ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board...
July 23 2019 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed
Brunie H. Felding, Ph.D., Associate Professor, Department of
Molecular Medicine, Scripps Research Institute, California Campus,
to the Scientific Advisory Board (SAB).
ChromaDex CEO Rob Fried stated, “We are intrigued by what we
have learned about NAD precursors and breast cancer prevention and
treatment from Dr. Felding’s research, and share her vision for
future studies and the impact the results could have for so many
people battling this horrible disease.”
The group of scientists Dr. Felding leads at Scripps has
conducted research that has shown that increasing NAD+ with the B3
vitamin nicotinamide prevented breast cancer development in mice.
Her research findings in the area of mechanisms and inhibition of
tumor metastasis have been published in dozens of journals
including Cancer Cell, Journal of Clinical Investigation and the
Journal of Neuro-Oncology.
“I’m honored to join the ChromaDex Scientific Advisory Board and
partner with world-leading scientists to further progress the
growing body of science on the safety and full therapeutic
treatment and preventative potential of NAD+ supplementation for
breast cancer," said Dr. Felding.
The goal of Dr. Felding’s research is to understand mechanisms
of cancer progression and to develop new regimens for prevention
and treatment. Dr. Felding received her Ph.D. in Biochemistry from
Philipps University Marburg, Germany in 1984; and Master of Science
degree in Biology from Justus-Liebig University of Giessen, Germany
in 1980. After post-doctoral studies at the Fred Hutchinson Cancer
Research Center (Seattle) and Scripps Research (La Jolla) she led a
pharmaceutical research group at Merck (Germany) before returning
to Scripps where she was appointed to Associate Professor in
2003. For more information about her research, visit:
https://www.scripps.edu/felding/.
Dr. Felding’s professional background also includes serving on
the Board of Directors of the Metastasis Research Society (2010 –
2014).
To date, ChromaDex has invested millions of dollars in safety
and human clinical trials on its patent-protected NR (commercially
known as Niagen) and has entered research agreements with more than
160 leading institutions for research, including Dartmouth, the
National Institutes of Health, University of Iowa, and the Scripps
Research Institute.
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at http://www.chromadex.com to which
ChromaDex regularly posts copies of its press releases as well as
additional and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Senior Director of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024